Taiho Oncology, Inc. clinical trials

A subsidiary of Otsuka Holdings Co., Ltd.

The registry lists 66 studies whose lead sponsor is Taiho Oncology, Inc.. 9 are recruiting or about to start. Per ClinicalTrials.gov, last updated Oct 13, 2026.

Studies

Recruiting first, then most recently updated. Showing 50 of 66. List all 66 → · All Otsuka Holdings Co., Ltd. studies →

• A Study to Assess Zipalertinib Versus Placebo in Participants With Early Stage NSCLC With Uncommon EGFR Mutations, Following Complete Tumor ResectionRecruitingNCT07128199Phase 3

  Sponsor listed in the registry: Taiho Oncology, Inc.

• A Study of ARC-02 in B-cell NHLRecruitingNCT07691606Phase 1

  Sponsor listed in the registry: Taiho Oncology, Inc.

• A Study of Zipalertinib in Patients With Advanced Non-Small Cell Lung Cancer With Epidermal Growth Factor Receptor (EGFR) Exon 20 Insertions or Other Uncommon Mutation.RecruitingNCT05967689Phase 2

  Sponsor listed in the registry: Taiho Oncology, Inc.

• A Multi-phase Study of ASTX030 (Azacitidine and Cedazuridine) in Myeloid Neoplasm Alone or in Combination With Venetoclax in AML (AZTOUND Study)RecruitingNCT04256317Phase 2/3

  Sponsor listed in the registry: Taiho Oncology, Inc.

• Study of Futibatinib in Patients With Advanced Cholangiocarcinoma With FGFR2 Fusion or RearrangementRecruitingNCT05727176Phase 2

  Sponsor listed in the registry: Taiho Oncology, Inc.

• A Study for Participants Who Participated in Prior Clinical Studies of ASTX727 (Standard Dose)Enrolling by invitationNCT04093570Phase 2

  Sponsor listed in the registry: Taiho Oncology, Inc.

• An EAP Treatment Protocol of ZipalertinibAvailableNCT07601399

  Sponsor listed in the registry: Taiho Oncology, Inc.

• Study to Evaluate the Pharmacokinetics and Safety of Oral Decitabine and Cedazuridine in Cancer Patients With Hepatic ImpairmentRecruitingNCT04953910Phase 1

  Sponsor listed in the registry: Taiho Oncology, Inc.

• Study to Evaluate the Pharmacokinetics and Safety of Oral Decitabine and Cedazuridine in Cancer Patients With Renal ImpairmentRecruitingNCT04953897Phase 1

  Sponsor listed in the registry: Taiho Oncology, Inc.

• A Study of Tolinapant in Combination With Oral Decitabine/Cedazuridine and Oral Decitabine/Cedazuridine Alone in Participants With Relapsed/Refractory Peripheral T-cell Lymphoma (R/R PTCL)TerminatedNCT05403450Phase 1

  Sponsor listed in the registry: Taiho Oncology, Inc.

• Pharmacokinetics, Safety, and Efficacy of ASTX727 in Combination With Venetoclax in Acute Myeloid Leukemia (AML)Active, not recruitingNCT04657081Phase 1/2

  Sponsor listed in the registry: Taiho Oncology, Inc.

• Phase 2 Futibatinib in Combination With PD-1 Antibody Based Standard of Care in Solid TumorsActive, not recruitingNCT05945823Phase 2

  Sponsor listed in the registry: Taiho Oncology, Inc.

• REZILIENT3 (REsearching ZIpaLertinib In Egfr Non-small Cell Lung Cancer Tumors)Active, not recruitingNCT05973773Phase 3

  Sponsor listed in the registry: Taiho Oncology, Inc.

• Futibatinib in Patients Previously Enrolled in an Antecedent Futibatinib as Monotherapy or Combination Therapy.Active, not recruitingNCT06506955Phase 2/3

  Sponsor listed in the registry: Taiho Oncology, Inc.

• Phase 1-2 Study of Low Dose ASTX727 (ASTX727 LD) in Lower Risk MDSCompletedNCT03502668Phase 1/2

  Sponsor listed in the registry: Taiho Oncology, Inc.

• A Study of TAS3351 in NSCLC Patients With EGFRmtTerminatedNCT05765734Phase 1

  Sponsor listed in the registry: Taiho Oncology, Inc.

• Phase 1-2 Study of ASTX660 in Subjects With Advanced Solid Tumors and LymphomasActive, not recruitingNCT02503423Phase 1/2

  Sponsor listed in the registry: Taiho Oncology, Inc.

• Expanded Access Study of TAS-120 in Patients With Advanced Cholangiocarcinoma Harboring FGFR2 Gene RearrangementsApproved for marketingNCT04507503

  Sponsor listed in the registry: Taiho Oncology, Inc.

• Futibatinib and Pembrolizumab Combination in the Treatment of Advanced or Metastatic Urothelial CarcinomaTerminatedNCT04601857Phase 2

  Sponsor listed in the registry: Taiho Oncology, Inc.

• A Study of TAS-120 in Patients With Metastatic Breast CancerTerminatedNCT04024436Phase 2

  Sponsor listed in the registry: Taiho Oncology, Inc.

• A Study of TAS2940 in Participants With Locally Advanced or Metastatic Solid Tumor CancerTerminatedNCT04982926Phase 1

  Sponsor listed in the registry: Taiho Oncology, Inc.

• Futibatinib in Patients With Specific FGFR AberrationsTerminatedNCT04189445Phase 2

  Sponsor listed in the registry: Taiho Oncology, Inc.

• Study of ASTX029 in Subjects With Advanced Solid TumorsCompletedNCT03520075Phase 1/2

  Sponsor listed in the registry: Taiho Oncology, Inc.

• Study of ASTX295 in Patients With Solid Tumors With Wild-Type p53TerminatedNCT03975387Phase 1

  Sponsor listed in the registry: Taiho Oncology, Inc.

• A Study of TAS-120 in Patients With Advanced Solid TumorsCompletedNCT02052778Phase 1/2

  Sponsor listed in the registry: Taiho Oncology, Inc.

• A Study of TAS0612 in Participants With Advanced or Metastatic Solid Tumor CancerTerminatedNCT04586270Phase 1

  Sponsor listed in the registry: Taiho Oncology, Inc.

• Futibatinib Versus Gemcitabine-Cisplatin Chemotherapy as First-Line Treatment of Patients With Advanced Cholangiocarcinoma Harboring FGFR2 Gene RearrangementsTerminatedNCT04093362Phase 3

  Sponsor listed in the registry: Taiho Oncology, Inc.

• A Study of TAS1440 With ATRA in Subjects With r/r AMLTerminatedNCT04282668Phase 1

  Sponsor listed in the registry: Taiho Oncology, Inc.

• Phase III Study of Trifluridine/Tipiracil With and Without Bevacizumab in Refractory Metastatic Colorectal Cancer PatientsCompletedNCT04737187Phase 3

  Sponsor listed in the registry: Taiho Oncology, Inc.

• Diffuse Gastric and Esophagogastric Junction Cancer S-1 TrialTerminatedNCT01285557Phase 3

  Sponsor listed in the registry: Taiho Oncology, Inc.

• A Randomized Phase 2 Trial of TAS-114 in Combination With S-1 Versus S-1CompletedNCT02855125Phase 2

  Sponsor listed in the registry: Taiho Oncology, Inc.

• Study of TAS-102 in Patients With Metastatic Colorectal Cancer Refractory to Standard ChemotherapiesCompletedNCT01607957Phase 3

  Sponsor listed in the registry: Taiho Oncology, Inc.

• Study of TAC-101 as Second Line Treatment in Patients With Advanced Hepatocellular Carcinoma Who Received Sorafenib as First Line TherapyTerminatedNCT00687596Phase 2

  Sponsor listed in the registry: Taiho Oncology, Inc.

• Phase 1b/2 Study of Futibatinib in Combination With Binimetinib in Patients With Advanced KRAS Mutant CancerTerminatedNCT04965818Phase 1

  Sponsor listed in the registry: Taiho Oncology, Inc.

• Phase 2 Study of S-1 in Advanced or Metastatic Pancreatic CancerCompletedNCT00651742Phase 2

  Sponsor listed in the registry: Taiho Oncology, Inc.

• A Safety and Efficacy Study in Patients With Gastric CancerCompletedNCT00400179Phase 3

  Sponsor listed in the registry: Taiho Oncology, Inc.

• Phase 2 Study of TAC-101 Combined With Transcatheter Arterial Chemoembolization (TACE) Versus TACE Alone in Japanese Patients With Advanced Hepatocellular CarcinomaTerminatedNCT00667628Phase 2

  Sponsor listed in the registry: Taiho Oncology, Inc.

• Expanded Access Study of TAS-102 in Patients With Metastatic Colorectal CancerApproved for marketingNCT02286492

  Sponsor listed in the registry: Taiho Oncology, Inc.

• A Study of TAS0728 in Patients With Solid Tumors With HER2 or HER3 AbnormalitiesTerminatedNCT03410927Phase 1

  Sponsor listed in the registry: Taiho Oncology, Inc.

• Study Comparing the Pharmacokinetics of FTD as a Component of TAS-102 With FTD AloneCompletedNCT01867866Phase 1

  Sponsor listed in the registry: Taiho Oncology, Inc.

• Study of the Mass Balance of Oral FTD and TPI as Components of TAS-102 in Patients With Advanced Solid TumorsCompletedNCT02031055Phase 1

  Sponsor listed in the registry: Taiho Oncology, Inc.

• A Phase I Study of TAS-102 in Patients With Advanced Solid Tumors With Hepatic ImpairmentCompletedNCT02301104Phase 1

  Sponsor listed in the registry: Taiho Oncology, Inc.

• Dose-escalating, Safety, Tolerability and PK Study of TAS-119 in Combination With Paclitaxel in Patients With Advanced Solid TumorsTerminatedNCT02134067Phase 1

  Sponsor listed in the registry: Taiho Oncology, Inc.

• A Dose Finding Study Followed by a Safety and Efficacy Study for Patients With Multiple Myeloma or LymphomaTerminatedNCT02978235Phase 1

  Sponsor listed in the registry: Taiho Oncology, Inc.

• Study Comparing the Bioavailability of TAS-102 Tablets to an Oral Solution Containing Equivalent Amounts of FTD and TPICompletedNCT01874522Phase 1

  Sponsor listed in the registry: Taiho Oncology, Inc.

• A Phase I Study of TAS-102 in Patients With Advanced Solid Tumors With Renal ImpairmentCompletedNCT02301117Phase 1

  Sponsor listed in the registry: Taiho Oncology, Inc.

• A Safety, Tolerability and Pharmacokinetic Study of TAS-114 in Combination With Capecitabine in Patients With Advanced Solid TumorsCompletedNCT02025803Phase 1

  Sponsor listed in the registry: Taiho Oncology, Inc.

• Study to Evaluate the Cardiac Safety of TAS-102 in Patients With Advanced Solid TumorsCompletedNCT01867879Phase 1

  Sponsor listed in the registry: Taiho Oncology, Inc.

• A Phase 2 Study Comparing TAS-102 Versus Topotecan or Amrubicin to Treat Small Cell Lung Cancer Following Platinum-Based ChemotherapyTerminatedNCT01904253Phase 2

  Sponsor listed in the registry: Taiho Oncology, Inc.

• Evaluating Patients With Varying Degrees of Renal FunctionCompletedNCT00398307Phase 1

  Sponsor listed in the registry: Taiho Oncology, Inc.